Figure 1
From: IGF-1 in autosomal dominant cerebellar ataxia - open-label trial
These charts with mean and standard deviation lines show four-monthly score changes from baseline on the scale for the assessment and rating of ataxia (SARA) during the first year of treatment with IGF-1. A significant improvement in SARA scores was observed for all patients (26) (top), and the SCA3 (19 patients) (middle), and SCA7 (6 patients) (bottom) subgroups after the first year of IGF-1 treatment.